Lifetime management of aortic stenosis represents a growing procedural and clinical challenge. With recent clinical trials indicating that transcatheter aortic valve replacement (TAVR) is at least on par with surgical aortic valve replacement (SAVR) in treating lower risk patients, there has been a rise in TAVR uptake in younger, lower risk patients, leading to an increased likelihood of bioprosthetic valve degradation within a patient’s lifetime. This shift in treatment has changed the landscap…